Figure S1. Topical Befetupitant treatment in the alkali burn model. (A) Corneal opacity score after 4 days of treatment was similar in the topical Befetupitant and DMSO groups. Befetupitant (0.4 and 1.6 mg/mL) reduced hemangiogenesis at slit-lamp examination; (B, C) corneal whole-mount showed significantly reduced CD31+ vessels and LYVE1+ lymphatics vessels in the Befetupitant-treated groups. Histograms represent mean values ± SEM; *P < 0.05 (n = 6).